Papers/PMID:41531219
Comparative efficacy and safety of warfarin and direct oral anticoagulants in patients with end-stage kidney disease and atrial fibrillation.
The Korean journal of internal medicine2026The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
warfarin — decreases all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Both warfarin (IPTW aHR, 0.53; 95% CI, 0.38–0.74; p < 0.001) and DOACs (aHR, 0.57; 95% CI, 0.43–0.78; p < 0.001) were associated with lower all-cause mortality compared with no anticoagulation (Table 3, Fig. 2, and Supplementary Fig. 1).”
Quoted verbatim from Comparative efficacy and safety of warfarin and direct oral anticoagulants in patients with end-stage kidney disease and atrial fibrillation.. - Study
- cohort
- Population
- Korean patients with end-stage kidney disease on dialysis and nonvalvular atrial fibrillation; warfarin compared with no anticoagulation, inverse-probability-weighted retrospective cohort
Effect 0.53 hazard ratio, 95% CI 0.38 to 0.74
Comparative efficacy and safety of warfarin and direct oral anticoagulants in patients with end-stage kidney disease and atrial fibrillation.2026PMID:41531219Permalink